Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Kenichi Nomoto"'
Autor:
Sharon McGonigle, Utpal Majumder, Donna Kolber-Simonds, Jiayi Wu, Andrew Hart, Thomas Noland, Karen TenDyke, Daniel Custar, Danyang Li, Hong Du, Maarten H. D. Postema, W. George Lai, Natalie C. Twine, Mary Woodall-Jappe, Kenichi Nomoto
Publikováno v:
Cell Communication and Signaling, Vol 17, Iss 1, Pp 1-14 (2019)
Abstract Background Chlorotoxin (Cltx) isolated from scorpion venom is an established tumor targeting and antiangiogenic peptide. Radiolabeled Cltx therapeutic (131I-TM601) yielded promising results in human glioma clinical studies, and the imaging a
Externí odkaz:
https://doaj.org/article/0260063af8414162a61d45c6971191f1
Autor:
Yu Kato, Kimiyo Tabata, Takayuki Kimura, Ayako Yachie-Kinoshita, Yoichi Ozawa, Kazuhiko Yamada, Junichi Ito, Sho Tachino, Yusaku Hori, Masahiro Matsuki, Yukiko Matsuoka, Samik Ghosh, Hiroaki Kitano, Kenichi Nomoto, Junji Matsui, Yasuhiro Funahashi
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212513 (2019)
Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors. We investigated the immunomodulatory activities of lenvatinib in the tumor microenvir
Externí odkaz:
https://doaj.org/article/a3add2de47a44a519a9f34fb4324f9ca
Autor:
Diana I. Albu, Zichun Wang, Kuan-Chun Huang, Jiayi Wu, Natalie Twine, Sarah Leacu, Christy Ingersoll, Lana Parent, Winnie Lee, Diana Liu, Renee Wright-Michaud, Namita Kumar, Galina Kuznetsov, Qian Chen, Wanjun Zheng, Kenichi Nomoto, Mary Woodall-Jappe, Xingfeng Bao
Publikováno v:
OncoImmunology, Vol 6, Iss 8 (2017)
Reprogramming of immunosuppressive tumor microenvironment (TME) by targeting alternatively activated tumor associated macrophages (M2TAM), myeloid-derived suppressor cells (MDSC), and regulatory T cells (Tregs), represents a promising strategy for de
Externí odkaz:
https://doaj.org/article/0ad9b21d212e459193839200090fcdbd
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0dc734be5d9dd693e64ffcaa2e3da3
https://doi.org/10.1158/1541-7786.c.6545243.v1
https://doi.org/10.1158/1541-7786.c.6545243.v1
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
HLA class-I allele data along with mean HED values for the lenvatinib/pembrolizumab and MSK-IMPACT cohorts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e73d0d1f26fdffbd276973c64e2ff13
https://doi.org/10.1158/1541-7786.22526897.v1
https://doi.org/10.1158/1541-7786.22526897.v1
Autor:
Kenichi Nomoto, Mary Woodall-Jappe, Toshimitsu Uenaka, William H. Gerwick, Yoshihiko Kotake, Hajime Shimizu, Xiaojie Zhu, Hyeong-wook Choi, Steven Mathieu, Kuo-Ming Wu, Yongchun Shen, Karen Tendyke, Sergei Agoulnik, Krista Condon, Donna Kolber-Simonds, Sandeep Akare, Yimin Jiang, Zhihong Chen, Kuan-Chun Huang
Figure S1. Synthesis of [3H]apratoxin A. Figure S2. Synthesis of C.18-epi-apratoxin A. Figure S3. Apratoxin A in vitro IC50 against panels of human cancer cell lines. Table S1. Summary table for in vivo efficacy studies. Figure S4. Apratoxin A concen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c65eb6f8b62874049a2fbbb2e9b798
https://doi.org/10.1158/1535-7163.22504099.v1
https://doi.org/10.1158/1535-7163.22504099.v1
Autor:
Kenichi Nomoto, Mary Woodall-Jappe, Toshimitsu Uenaka, William H. Gerwick, Yoshihiko Kotake, Hajime Shimizu, Xiaojie Zhu, Hyeong-wook Choi, Steven Mathieu, Kuo-Ming Wu, Yongchun Shen, Karen Tendyke, Sergei Agoulnik, Krista Condon, Donna Kolber-Simonds, Sandeep Akare, Yimin Jiang, Zhihong Chen, Kuan-Chun Huang
Apratoxin A is a natural product with potent antiproliferative activity against many human cancer cell lines. However, we and other investigators observed that it has a narrow therapeutic window in vivo. Previous mechanistic studies have suggested it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1702da5e1eb71b2ce4a697dd456e12e0
https://doi.org/10.1158/1535-7163.c.6537622.v1
https://doi.org/10.1158/1535-7163.c.6537622.v1
Autor:
Timothy A. Chan, Robert J. Motzer, A. Ari Hakimi, Kenichi Nomoto, Yasuhiro Funahashi, Junji Matsui, Yukinori Minoshima, Yusuke Adachi, Pallavi Sachdev, Darren Feldman, Maria I. Carlo, Martin H. Voss, Ritesh Kotecha, Samuel Murray, Ed Reznik, Luc Morris, Doug Hoen, Kate Weiss, Mark Lee, Lynda Vuong, Cristina Valero, Vladimir Makarov, Chirag Krishna, Diego Chowell, Renzo G. DiNatale, Chung-Han Lee
Mutation annotation file (MAF) showing all nonsynonymous exonic mutations identified in the lenvatinib/pembrolizumab cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f1fd9c0a1913ce15bcfdab16d4fc29
https://doi.org/10.1158/1541-7786.22526900.v1
https://doi.org/10.1158/1541-7786.22526900.v1
Autor:
Kenichi Nomoto, Mary Woodall-Jappe, Toshimitsu Uenaka, William H. Gerwick, Yoshihiko Kotake, Hajime Shimizu, Xiaojie Zhu, Hyeong-wook Choi, Steven Mathieu, Kuo-Ming Wu, Yongchun Shen, Karen Tendyke, Sergei Agoulnik, Krista Condon, Donna Kolber-Simonds, Sandeep Akare, Yimin Jiang, Zhihong Chen, Kuan-Chun Huang
Figure S1. Synthesis of [3H]apratoxin A. Figure S2. Synthesis of C.18-epi-apratoxin A. Figure S3. Apratoxin A in vitro IC50 against panels of human cancer cell lines. Table S1. Summary table for in vivo efficacy studies. Figure S4. Apratoxin A concen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f53f6e76b6cb66b04a95e5af1c1cb98
https://doi.org/10.1158/1535-7163.22504102
https://doi.org/10.1158/1535-7163.22504102
Autor:
Yoichi Ozawa, Yasuhiro Funahashi, Takashi Owa, Hiroyuki Kouji, Kenichi Nomoto, Tomohiro Matsushima, Junji Matsui, Toshimitsu Uenaka, Akihiko Tsuruoka, Masao Iwata, Takenao Odagami, Masayuki Matsukura, Akira Yokoi, Taro Semba, Yu Kato, Kenji Kubara, Naomi Wakayama, Ikuo Kushida, Atsushi Takemura, Naoki Yoneda, Hitoshi Harada, Kazutaka Nakamoto, Masahiro Matsuki, Junichi Ito, Mai Uesugi, Takayuki Kimura, Atsumi Yamaguchi, Hiroshi Kamiyama, Kentaro Iso, Yuji Yamamoto, Satoshi Inoue, Yusaku Hori, Kazuhiko Yamada
The list of Topologically significant genes by RNA-Seq analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b281375c38e0afca97059249be1c48
https://doi.org/10.1158/0008-5472.22427412
https://doi.org/10.1158/0008-5472.22427412